H.C. Wainwright lowered the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $17 and keeps a Buy rating on the shares. The firm cites the company’s financing-related dilution for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics: Early-Stage Pipeline, Trial Setbacks and High Risks on the Road to Profitability
- CytomX Earnings Call Highlights Varseta-M Momentum
- CytomX Therapeutics reports Q1 EPS (10c), consensus (11c)
- CytomX Therapeutics participates in a conference call with JPMorgan
- CytomX Therapeutics Signals Progress in Varseta-M Trial